Skip Navigation

Strengthening the evidence for maternal and child health programs

Search Results: MCHLine

Items in this list may be obtained from the sources cited. Contact information reflects the most current data about the source that has been provided to the MCH Digital Library.


Displaying records 1 through 7 (7 total).

Barzel R, Holt K, Kolo S. 2018. Prescribing opioids for women of reproductive age: Information for dentists. Washington, DC: National Maternal and Child Oral Health Resource Center, 4 pp.

Annotation: This practice guidance provides an overview of pain management for dental procedures for women of reproductive age. It discusses pharmacological considerations for pregnant women (pharmaceutical agents and indications, contraindications, and special considerations), neonatal opioid withdrawal syndrome, guidelines for providing opioids, managing acute dental pain, and guidelines for discharging women with opioid prescriptions. Information about prescription drug monitoring programs is included. [Funded by the Maternal and Child Health Bureau]

Contact: National Maternal and Child Oral Health Resource Center, Telephone: (202) 784-9771 E-mail: OHRCinfo@georgetown.edu Web Site: https://www.mchoralhealth.org Available from the website.

Keywords: , Drug addiction, Guidelines, Narcotics, Neonatal abstinence syndrome, Oral health, Pain relieving drugs, Pregnant women, Prescription drugs

Children's Safety Network. 2016. Medication abuse prevention: 2016 resource guide. Waltham, MA: Children's Safety Network, 19 pp.

Annotation: This guide describes organizations, policy and legislation, prevention programs, publications, and webinars focused on prescription drug overdose prevention among youth and young adults. Contents include descriptions of reports, guides, toolkits, campaigns, website, iinitiatives, and research studies. Each item includes a short description and a link to the resource itself. Information about child safety and neonatal abstinence syndrome are included. [Funded by the Maternal and Child Health Bureau]

Contact: Children's Safety Network, Education Development Center, 43 Foundry Avenue, Waltham, MA 02453-8313, Telephone: (617) 618-2918 Fax: (617) 969-9186 E-mail: csninfo@edc.org Web Site: http://www.childrenssafetynetwork.org Available from the website.

Keywords: Adolescents, Children, Drug effects, Infants, Legislation, Multimedia, Neonatal abstinence syndrome, Policy development, Prescription drugs, Resource materials, Resources for professionals, Safety, Substance abuse prevention, Substance abuse prevention programs, Young adults

Ko HY, Patrick SW, Tong VT, Patel R, Lind JN, Barfield WD. 2016. Incidence of neonatal abstinence syndrome: 28 states, 1999–2013. Morbidity and Mortality Weekly Report 65(31):799–802,

Annotation: This report examines state trends in neonatal abstinence syndrome (NAS) incidence using all-payer, hospital inpatient delivery discharges compiled in the State Inpatient Databases of the Healthcare Cost and Utilization Project (HCUP) during 1999–2013. The findings underscore the importance of state-based public health programs to prevent unnecessary opioid use and to treat substance use disorders during pregnancy, as well as decrease the incidence of NAS.

Contact: Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329-4027, Telephone: (800) 232-4636 Secondary Telephone: (888) 232-6348 E-mail: cdcinfo@cdc.gov Web Site: http://www.cdc.gov Available from the website.

Keywords: Drug use during pregnancy, Measures, Neonatal abstinence syndrome, Newborn infants, Opiates, Pregnant women, State programs, Statistical data, Substance use disorders, Trends

National Institute for Health Care Management Foundation. 2015. Reducing neonatal abstinence syndrome in Tennessee. Washington, DC: National Institute for Health Care Management Foundation, 2 pp. (Women, children & adolescents)

Annotation: This fact sheet highlights partnerships to address the neonatal abstinence syndrome (NAS) epidemic in Tennessee. Topics include efforts to expand a community-based program to assist mothers with substance abuse problems and ensure a drug-free and safe home for their newborns; provide start-up costs for a regional detox center for women addicted to prescription drugs; research the effectiveness of detox from opiate drugs during pregnancy, and the long-term effect of detox treatment on NAS rates in the state; and establish a hospital-based NAS treatment process.

Contact: National Institute for Health Care Management Foundation, 1225 19th Street, N.W., Suite 710, Washington, DC 20036, Telephone: (202) 296-4426 Fax: (202) 296-4319 E-mail: http://www.nihcm.org/contact Web Site: http://www.nihcm.org Available from the website.

Keywords: Drug addiction, Drug use during pregnancy, Financing, Neonatal abstinence syndrome, Newborn infants, Opiates, Postpartum care, Pregnant women, Prenatal care, Prevention program, State initiatives, Substance abuse treatment, Tennessee

Ramakrishnan M. 2014. Neonatal abstinence syndrome: How states can help advance the knowledge base for primary prevention and best practices of care. Arlington, VA: Association of State and Territorial Health Officials, 24 pp.

Annotation: This report describes opportunities to avert or ameliorate the outcome of neonatal abstinence syndrome (NAS) along a continuum of care spanning timeframes in the mother's and infant's life and the role of state health agencies. Topics include surveillance for NAS-affected infants and the sources of maternal opiate use; reimbursement for using screening protocols to detect substance abuse early in pregnancy and withdrawal signs in newborns; development of measures to ensure follow-up with opioid-dependent women and receipt of comprehensive services; and collaborative efforts to strengthen clinical standards for identification, management, and follow-up with NAS-affected infants and their families. A state index of resources is included.

Contact: Association of State and Territorial Health Officials, 2231 Crystal Drive, Suite 450, Arlington, VA 22202, Telephone: (202) 371-9090 Fax: (571) 527-3189 Web Site: http://www.astho.org Available from the website.

Keywords: Comprehensive health care, Intervention, Neonatal abstinence syndrome, Neonatal addiction, Newborn infants, Opiates, Population surveillance, Primary prevention, Screening, State health agencies, Substance use

National Institute for Health Care Management Foundation and Association of State and Territorial Health Officials. 2014. Neonatal abstinence syndrome: Strategies for states and health plans. Washington, DC: National Institute for Health Care Management Foundation, multiple items.

Annotation: These resources, from a webinar held on July 16, 2014, highlight strategies for preventing and treating neonatal abstinence syndrome (NAS). Contents include a recording of the speaker's presentations (1 hour, 27 min., 23 sec.), the webinar agenda and speaker biographies, and related materials. Topics include recent trends in opioid abuse and NAS, with an overview of federally-led prevention efforts; the impact of rising NAS rates across the states, including implications for Medicaid and examples of state-level action; a health plan-led initiative to improve care coordination and social support for pregnant women in treatment for addiction; and the latest in NAS treatment, and an assessment of where public and private investments would be most beneficial.

Contact: National Institute for Health Care Management Foundation, 1225 19th Street, N.W., Suite 710, Washington, DC 20036, Telephone: (202) 296-4426 Fax: (202) 296-4319 E-mail: http://www.nihcm.org/contact Web Site: http://www.nihcm.org Available from the website.

Keywords: Analgesic drugs, Collaboration, Drug addiction, Drug effects, Federal initiatives, Health care systems, Model programs, Neonatal abstinence syndrome, Newborns, Opiates, Pregnant women, Prevention programs, Public private partnerships, State MCH programs, Substance abuse treatment

Washington State Department of Health, Health Education Resource Exchange. 2013. Guidelines for testing and reporting drug exposed newborns in Washington state. Olympia, WA: Washington State Department of Health, Health Education Resource Exchange, 16 pp.

Annotation: This document provides guidance to hospitals, health care providers and affiliated professionals about maternal drug screening, laboratory testing, and reporting of drug-exposed newborns delivered in Washington State. Contents include indicators for testing, hospital policy, newborn and maternal risk indicators, consent issues for testing, newborn drug testing, management of a newborn with positive drug toxicology, and reporting to Children's Administration. Appendices include references and resources, guidelines for obtaining consent, a sample letter, neonatal abstinence syndrome scoring system, and information on Washington's Children's Administration prenatal substance abuse policy.

Contact: Washington State Department of Health, P.O. Box 47890, Olympia, WA 98504-7890, Telephone: (800) 525-0127 Secondary Telephone: (360) 236-4030 Web Site: http://www.doh.wa.gov Available from the website.

Keywords: Drug use during pregnancy, Guidelines, Hospital services, Infant health, Neonatal abstinence syndrome, Neonatal screening, Newborn infants, State initiatives, State social service agencies, Substance abusing pregnant women, Substance use screening, Washington

   

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U02MC31613, MCH Advanced Education Policy, $3.5 M. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.